Fresenius Medical Care AG/€FME
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Fresenius Medical Care AG
Fresenius Medical Care, listed under the ticker FME, is a global provider of dialysis services and products for individuals diagnosed with chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in the healthcare sector. Beyond dialysis, Fresenius Medical Care offers a range of other services, including hospital management and related healthcare services, advancing its position as a comprehensive healthcare provider internationally.
- Ticker
- €FME
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 109,698
- Headquarters
- Bad Homburg, Germany
- Website
- www.freseniusmedicalcare.com
FME Metrics
BasicAdvanced
€11B
13.74
€3.01
0.79
€1.49
3.60%
Price and volume
Market cap
€11B
Beta
0.79
52-week high
€45.90
52-week low
€34.58
Average daily volume
961K
Dividend rate
€1.49
Financial strength
Current ratio
0.992
Quick ratio
0.575
Long term debt to equity
0.575
Total debt to equity
0.792
Dividend payout ratio (TTM)
48.64%
Interest coverage (TTM)
4.85%
Profitability
EBITDA (TTM)
2,882.677
Gross margin (TTM)
26.45%
Net profit margin (TTM)
4.23%
Operating margin (TTM)
11.05%
Effective tax rate (TTM)
22.61%
Revenue per employee (TTM)
€180,000
Management effectiveness
Return on assets (TTM)
3.94%
Return on equity (TTM)
7.84%
Valuation
Price to earnings (TTM)
13.738
Price to revenue (TTM)
0.58
Price to book
0.83
Price to tangible book (TTM)
-4.28
Price to free cash flow (TTM)
6.308
Free cash flow yield (TTM)
15.85%
Free cash flow per share (TTM)
6.556
Dividend yield (TTM)
3.60%
Forward dividend yield
3.60%
Growth
Revenue change (TTM)
-0.83%
Earnings per share change (TTM)
23.49%
3-year revenue growth (CAGR)
0.03%
10-year revenue growth (CAGR)
1.92%
3-year earnings per share growth (CAGR)
25.25%
10-year earnings per share growth (CAGR)
-1.42%
3-year dividend per share growth (CAGR)
9.98%
10-year dividend per share growth (CAGR)
6.78%
What the Analysts think about FME
Analyst ratings (Buy, Hold, Sell) for Fresenius Medical Care AG stock.
Analyst projections of the future price of Fresenius Medical Care AG stock.
Bulls say / Bears say
FME25+ delivered €74 million of additional savings in Q3, while Care Delivery operating income excluding special items rose 4%. This suggests the restructuring is helping the core treatment business absorb cost pressure. (Fresenius Medical Care)
The 5008X system had reached 16% of US clinic machines and 1.3 million treatments by Q3, and the company launched its multiFiltratePRO critical-care system in the US. These products could support growth beyond established dialysis services. (Fresenius Medical Care)
International Care Delivery provides a counterweight to US weakness: Q3 revenue grew 6% organically and same-market treatments rose 1.4%. (Fresenius Medical Care)
US same-market treatments fell 1.1% in Q3, the third consecutive quarterly decline, and Fresenius Medical Care narrowed its 2026 operating-income outlook to flat-to-mid-single-digit decline. This is a concern in its largest market, which accounts for more than half of revenue. (Reuters)
Management expects TDAPA reimbursement changes to create a €300 million to €350 million operating-income headwind in 2027. That would add pressure to earnings after the company has already warned of difficult reimbursement conditions. (Investing.com)
Special charges are weighing heavily on reported results: Q3 operating income fell 19% and net income fell 42%, including €108 million of costs from the China strategy change. The continuing transformation also carries substantial costs, with €350 million of one-off costs expected in 2026. (Fresenius Medical Care)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
FME Financial Performance
Revenues and expenses
FME Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing FME
AllEURUSDGBP
Fund name | Fund size | €FME weighting |
|---|---|---|
iShares DivDAX€EXSB | €562M | 1.38% |
iShares EURO STOXX Mid€DJMC | €595M | 0.97% |
iShares EURO STOXX Mid Cap£DJMC | €595M | 0.97% |
iShares Dax ESG€EXIA | €127M | 0.67% |
iShares Edge MSCI Europe Value Factor€CEMS | €2.6B | 0.52% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.